Rimonbant shows promise in addressing multiple risk factors

ently under investigation for the treatment of obesity and related metabolic risk factors, as well as smoking cessation. Rimonabant selectively targets and blocks the CB1 receptors located in central and peripheral areas of the body (such as adipocytes or fat cells), associated with lipid and glucose metabolism, and normalizes the over-activation associated with exaggerated food intake and/or smoking. This action results in weight loss, improvement of cardiovascular/ metabolic risk factors in overweight/obese patients and reduces tobacco dependence without post cessation weight gain in people who smoke.

RIO-Lipids is the first of four Phase III studies comprising the RIO Program examining the effectiveness and safety of rimonabant in achieving weight loss and improving metabolic risk factors in 6,600 obese patients world-wide. Within the RIO clinical trial program, rimonabant is being investigated in specific groups of patients at high risk for cardiovascular disease in the RIO-Diabetes and RIO-Lipids studies.

RIO-North America, RIO-Europe and RIO-Diabetes are all ongoing. The findings of these studies are expected to be announced over the next twelve months.

Rimonabant is also under investigation as an aid to smoking cessation. Three active Phase III clinical trials are underway within the framework of the STRATUS (STudies with Rimonabant And Tobacco USe) clinical trial program. The results of the first of these trials, STRATUS-US, were also presented today at the American College of Cardiology. The study showed that rimonabant 20mg helped smokers who had previously attempted to quit, enabled them to achieve abstinence without post cessation weight gain at double the rate obtained in patients treated with placebo.


Located in the heart of Quebec's historic capital city, University Laval is one of Canada's leading universities. Among the to

Contact: Glenn Lehrman

Page: 1 2 3 4 5 6

Related biology news :

1. New study shows hope for treating inhalant abuse
2. Chemical derived from vitamin-E shows early promise as cancer drug
3. Cancer vaccine based on pathogenic listeria bacteria shows promise targeting metastases
4. Trial shows which brain cancer patients benefit from temozolomide
5. New research shows plants can shuffle and paste gene pieces to generate genetic diversity
6. Preclinical safety study shows adipose-derived stem cells improve heart function after heart attack
7. Simian virus 40 not associated with non-Hodgkin lymphoma, study shows
8. A probable cause for high blood pressure identified - shows links with diabetes
9. Blue marlin in gulf have high mercury levels, A&M study shows
10. New research shows air pollution can reduce childrens lung function
11. Pneumococcal vaccine reduces ear infections, pneumonia, new study shows

Post Your Comments:

(Date:8/5/2020)... ... , ... Regenative Labs has received approval from the Centers for Medicare & ... first Wharton’s jelly allografts to be assigned a Q code and be approved for ... Wharton’s jelly allograft product to be recognized as a 361 HCT/P by CMS regulated ...
(Date:7/18/2020)... ... July 16, 2020 , ... A study has been published ... Neoasis™ active noise control device to attenuate typical noises in a simulated neonatal ... the alarm sounds from patient monitors, ventilators and other bedside devices that would ...
(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. http://www.altrubio.com ... a biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European ... J Martin of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... FARMS, Mich. (PRWEB) , ... August 12, 2020 ... ... Consulting Group, Inc. (EMMA International), a global leader in FDA compliance consulting ... of the nation’s fastest-growing private companies. The list represents a unique look at ...
(Date:8/3/2020)... (PRWEB) , ... August 03, 2020 , ... ... collection, today announced Jim Corrigan, President and CEO has been named one of ... broad cross-section of industry sectors, PharmaVoice 100 honorees are selected based on how ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is ... $3950. With 50 million stem cells total, patients may choose which extremities they would ... for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... transmitter systems that can be configured to drive Klystrons, TWTs, IOTs, and magnetrons. ... drive one or two switches in a push-pull configuration; yielding fast fall time ...
Breaking Biology Technology:
Cached News: